Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology
Name	Alliance for Clinical Trials in Oncology
Formation	2014 (merger)
Type	Clinical trial cooperative group
Headquarters	Chicago, Illinois
Region	United States
Leader title	Executive Director
Leader name	Christopher J. (Chris)/entity

Alliance for Clinical Trials in Oncology is a United States-based cooperative clinical trials group formed by the merger of major National Cancer Institute-funded networks. It conducts oncology trials across sarcoma, breast, lung, hematologic, pediatric, and geriatric oncology settings and works with academic centers, community hospitals, and international partners. The organization designs, implements, and analyzes interventional and translational studies with multidisciplinary teams drawn from cancer centers, cooperative groups, research networks, and regulatory agencies.

History

The group emerged from a consolidation of legacy cooperative groups following directives from the National Cancer Institute and policies associated with the United States Department of Health and Human Services and the National Institutes of Health to streamline clinical research networks. Its antecedents include the North Central Cancer Treatment Group, the Cancer and Leukemia Group B, and the American College of Surgeons Oncology Group, each with histories tied to institutions like Mayo Clinic, University of Chicago, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute. The merger followed strategic reviews similar to reorganizations seen in National Comprehensive Cancer Network alignments and mirrored consolidation trends in networks such as the Pediatric Oncology Group and the Children's Oncology Group. Early leadership included investigators with affiliations to University of Michigan, Johns Hopkins University School of Medicine, University of California, San Francisco, and Fred Hutchinson Cancer Research Center. The group’s formation was noted in conjunction with policy discussions involving the Institute of Medicine and advisory committees convened at National Institutes of Health meetings held in Bethesda, Maryland.

Organization and Governance

Governance structures reflect models used by cooperative groups like the Southwest Oncology Group and the Eastern Cooperative Oncology Group. Committees include executive, protocol review, scientific, operations, and data safety monitoring boards with members from centers such as Columbia University Irving Medical Center, University of Pennsylvania, Stanford University School of Medicine, and Yale Cancer Center. The organizational chart aligns with standards from the Food and Drug Administration guidance for clinical trials and interfaces with institutional review boards at institutions such as Massachusetts General Hospital and Cleveland Clinic. Leadership rotates among chairs drawn from faculty at Washington University in St. Louis, University of Texas MD Anderson Cancer Center, University of Wisconsin School of Medicine and Public Health, and University of Alabama at Birmingham. Administrative operations coordinate with grant offices at Harvard Medical School and contracting units modeled after the Veterans Health Administration research networks.

Research Programs and Clinical Trials

Programs span solid tumor oncology, hematologic malignancies, radiation oncology, surgical oncology, translational science, and biostatistics, with trial designs influenced by methods from the Eastern Cooperative Oncology Group and statistical collaborations with the Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute. Protocol portfolios have included phase I, II, and III trials testing agents developed by pharmaceutical firms and evaluated under frameworks used by European Medicines Agency submissions and Food and Drug Administration Investigational New Drug studies. Trials have enrolled patients through cooperative relationships with networks such as Northeast Oncology Group affiliates, community sites like Kaiser Permanente, and international sites in partnership with institutions such as University of Toronto and Imperial College London. Investigator-initiated studies have integrated correlative science from cores at Broad Institute, molecular profiling with platforms pioneered at Memorial Sloan Kettering Cancer Center, and bioinformatics resources similar to those at National Cancer Institute’s GDC initiatives.

Collaborations and Partnerships

The organization partners with academic medical centers, pharmaceutical companies, biotechnology firms, patient advocacy groups, and regulatory agencies. Collaborations mirror consortia including ALLIANCE-like legacy groups working with industry partners such as Roche, Pfizer, Novartis, Merck, and AstraZeneca on cooperative trials, and with foundations like American Cancer Society and LIVESTRONG Foundation on survivorship research. International partnerships echo those of European Organisation for Research and Treatment of Cancer and include ties to cooperative groups in Canada, Australia, and the United Kingdom. Data-sharing arrangements reference standards used by The Cancer Genome Atlas and consortia like International Cancer Genome Consortium, and patient-reported outcomes initiatives coordinate with advocacy organizations such as Susan G. Komen.

Funding and Grants

Primary funding streams derive from grant awards administered by the National Cancer Institute under cooperative agreement mechanisms and supplemented by contracts with agencies such as the Department of Defense Congressionally Directed Medical Research Programs and investigator-initiated grants from the American Society of Clinical Oncology and philanthropic donors including Bill & Melinda Gates Foundation-style private funders. Industry-sponsored trial support comes from biopharmaceutical companies and venture-backed biotech startups. Financial oversight follows models applied by National Institutes of Health grants management offices and auditing standards similar to those at Office of Management and Budget-regulated entities.

Impact and Notable Contributions

The group has influenced clinical practice guidelines developed by the National Comprehensive Cancer Network and contributed data used in approvals by the Food and Drug Administration and label expansions anchored on trials run in multicenter cooperative settings. Its investigators have published in journals such as Journal of Clinical Oncology, Lancet Oncology, New England Journal of Medicine, Blood, and Cancer Research, and presented findings at conferences including the American Society of Clinical Oncology Annual Meeting, the European Society for Medical Oncology Congress, the American Society of Hematology Annual Meeting, and the Radiological Society of North America assembly. The cooperative model has informed cancer research policy deliberations at the Institute of Medicine and contributed training opportunities for fellows from programs at Johns Hopkins Hospital, UCLA Health, and Columbia University Medical Center.

Category:Oncology research organizations